FDA Approves New Sweetener, Advantame
Statement of CSPI Senior Scientist Lisa Lefferts
CSPI will be carefully reviewing the studies on Advantame.
However, an initial concern is that in a key cancer study in mice, the number of mice that survived to the end of the study was below FDA's own scientific recommendations, and is therefore inadequate to provide confidence in the safety of a chemical likely to be consumed by millions of people.
Contact Jeff Cronin (jcronin[at]cspinet.org) or Ariana Stone (astone[at]cspinet.org).